Clinical Trial Update: Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the oral JAK inhibitor AZD4205 in combination with osimertinib in patients with advanced non-small cell lung cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD4205
• Osimertinib (osimertinib)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Nonsmall Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED